These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 33743480)

  • 21. Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix.
    Di Giacomo AM; Giacobini G; Gandolfo C; Lofiego MF; Cusi MG; Maio M
    Eur J Cancer; 2021 Oct; 156():119-121. PubMed ID: 34428684
    [No Abstract]   [Full Text] [Related]  

  • 22. [Overview of COVID-19 vaccines licensed in the EU-from technology via clinical trial to registration].
    Hildt E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1237-1243. PubMed ID: 36257986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.
    Tenbusch M; Schumacher S; Vogel E; Priller A; Held J; Steininger P; Beileke S; Irrgang P; Brockhoff R; Salmanton-García J; Tinnefeld K; Mijocevic H; Schober K; Bogdan C; Yazici S; Knolle P; Cornely OA; Überla K; Protzer U;
    Lancet Infect Dis; 2021 Sep; 21(9):1212-1213. PubMed ID: 34332707
    [No Abstract]   [Full Text] [Related]  

  • 26. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
    Malek AE; Cornejo PP; Daoud N; Alam M
    Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments.
    Liao HT; Tung HY; Chou CT; Tsai HC; Yen YN; Tsai CY
    Scand J Rheumatol; 2022 Nov; 51(6):500-505. PubMed ID: 35638589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia.
    Crickx E; Moulis G; Ebbo M; Terriou L; Briantais A; Languille L; Limal N; Guillet S; Michel M; Mahevas M; Godeau B
    Br J Haematol; 2021 Dec; 195(5):703-705. PubMed ID: 34467525
    [No Abstract]   [Full Text] [Related]  

  • 29. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
    Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
    Front Immunol; 2022; 13():908108. PubMed ID: 35911701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
    Wang M; Wen W; Zhou M; Wang C; Feng ZH
    Am J Cardiol; 2022 Mar; 167():155-157. PubMed ID: 35063268
    [No Abstract]   [Full Text] [Related]  

  • 31. Mixing vaccines may boost immune responses.
    Vogel G
    Science; 2021 Jun; 372(6547):1138. PubMed ID: 34112673
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety and immunogenicity after 2 doses of the BNT162b2 COVID-19 vaccine in an early-phase oncology trial centre population.
    Malissen N; Ninove L; de Lamballerie X; André N; Gaudy-Marqueste C
    Eur J Cancer; 2021 Oct; 156():125-126. PubMed ID: 34438245
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial.
    Niyomnaitham S; Toh ZQ; Licciardi PV; Wongprompitak P; Srisutthisamphan K; Copeland KK; Chokephaibulkit K
    J Infect; 2022 Oct; 85(4):436-480. PubMed ID: 35728642
    [No Abstract]   [Full Text] [Related]  

  • 34. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
    Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
    J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report.
    Lasagna A; Lenti MV; Cassaniti I; Sacchi P
    Immunotherapy; 2022 Aug; 14(12):915-925. PubMed ID: 35694999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune thrombocytopenic purpura after SARS-CoV-2 vaccine.
    Candelli M; Rossi E; Valletta F; De Stefano V; Franceschi F
    Br J Haematol; 2021 Aug; 194(3):547-549. PubMed ID: 33934330
    [No Abstract]   [Full Text] [Related]  

  • 37. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.
    Terpos E; Zagouri F; Liontos M; Sklirou AD; Koutsoukos K; Markellos C; Briasoulis A; Papanagnou ED; Trougakos IP; Dimopoulos MA
    J Hematol Oncol; 2021 May; 14(1):86. PubMed ID: 34059088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant).
    Sandhu S; Bhatnagar A; Kumar H; Dixit PK; Paliwal G; Suhag DK; Patil C; Mitra D
    Dermatol Ther; 2021 Nov; 34(6):e15141. PubMed ID: 34546608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.
    Krzywicka K; Heldner MR; Sánchez van Kammen M; van Haaps T; Hiltunen S; Silvis SM; Levi M; Kremer Hovinga JA; Jood K; Lindgren E; Tatlisumak T; Putaala J; Aguiar de Sousa D; Middeldorp S; Arnold M; Coutinho JM; Ferro JM
    Eur J Neurol; 2021 Nov; 28(11):3656-3662. PubMed ID: 34293217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.